IBI305 is named as an intervention in 9 current clinical trials in our Mexico, Israel, China, Egypt and Japan registers. 2 are recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is National Cancer Institute (NCI) (7). The most-studied condition is Fallopian Tube High Grade Serous Adenocarcinoma.
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Fallopian Tube High Grade Serous Adenocarcinoma | 2 |
| EGFR Mutant NSCLC and Platinum Resistant Ovarian Cancer | 1 |
| Neck Squamous Cell Carcinoma of Unknown Primary | 1 |
| Recurrent Hypopharyngeal Squamous Cell Carcinoma | 1 |
| Recurrent Laryngeal Squamous Cell Carcinoma | 1 |
| Recurrent Laryngeal Verrucous Carcinoma | 1 |
| Colorectal Neuroendocrine Tumor G1 | 1 |
| Gastric Neuroendocrine Tumor G1 | 1 |
| Neuroendocrine Neoplasm | 1 |
| Neuroendocrine Tumor | 1 |
| Ovarian High Grade Serous Adenocarcinoma | 1 |
| Ovarian Seromucinous Carcinoma | 1 |
| Primary Peritoneal High Grade Serous Adenocarcinoma | 1 |
| Fallopian Tube Endometrioid Adenocarcinoma | 1 |
| Fallopian Tube Malignant Mixed Mesodermal (Mullerian) Tumor | 1 |
| FIGO Stage III Ovarian Cancer 2014 | 1 |
| Breast Adenocarcinoma | 1 |
| Endometrial Adenocarcinoma | 1 |
| Endometrial Adenosquamous Carcinoma | 1 |
| Endometrial Clear Cell Adenocarcinoma | 1 |
| Endometrial Serous Adenocarcinoma | 1 |
| Borderline Ovarian Mucinous Tumor | 1 |
| Ovarian Mucinous Cystadenocarcinoma | 1 |
| Recurrent Fallopian Tube Carcinoma | 1 |
| Recurrent Ovarian Carcinoma | 1 |
| Advanced Endometrial Carcinoma | 1 |
| Recurrent Endometrial Carcinoma | 1 |
| Lead sponsor | Trials |
|---|---|
| National Cancer Institute (NCI) | 7 |
| Innovent Biologics (Suzhou) Co. Ltd | 1 |
| NRG Oncology | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in Mexico | 8 | 2 |
| Clinical trials in Israel | 4 | 0 |
| Clinical trials in China | 1 | 0 |
| Clinical trials in Egypt | 1 | 0 |
| Clinical trials in Japan | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
9 current trials in our Mexico, Israel, China, Egypt and Japan registers name IBI305 as a drug or biological intervention, as of the registry sync on 1 October 2026. Completed and withdrawn studies are not counted.
Yes. 2 of the 9 trials are recruiting: 2 with sites in Mexico and 1 with sites in Japan. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
National Cancer Institute (NCI) (7), Innovent Biologics (Suzhou) Co. Ltd (1) and NRG Oncology (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how IBI305 works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how IBI305 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists IBI305 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 1 Oct 2026. How every register is built: methodology · fixes we have made: corrections log.